{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:11025495",
      "entity_text" : "cholesterol",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:9803963",
      "entity_text" : "GW501516",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Two-week clinical studies performed in healthy volunteers and moderately overweight subjects showed that the synthetic PPARdelta agonist GW501516 reduces fasting plasma triglyceride and increases HDL cholesterol concentrations, indicating that the targeting of PPARdelta may have beneficial effects in metabolic disorders.",
  "reading_complete" : "2020-07-28T12:01:24Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T11:54:55Z",
  "trigger" : "increases",
  "evidence" : [ "GW501516 reduces fasting plasma triglyceride and increases HDL cholesterol" ],
  "pmc_id" : "3161281",
  "score" : 0
}